KNOLL SYNTHROID CAMPAIGN MUST REFLECT "MATERIAL INFORMATION" IN UNPUBLISHED ARTICLE, FDA TELLS COMPANY: OPENING VOLLEY IN 1997 DEBATE ON JOURNAL REPRINTS?
Executive Summary
Knoll's dissemination of a 1993 article on Synthroid and competing levothyroxine products is misleading because the company has not disclosed "material information" in its possession about the issue, FDA charges in a Nov. 7 letter to the company.
You may also be interested in...
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011